{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039797","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.520789+00:00","generated_at":"2026-06-12T02:04:00.783164+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara Q2 net loss $71.1M; IND cleared for ATA3219; tab-cel BLA meeting scheduled","bullets":["Net loss of $71.1M ($0.68 per share) vs net income of $18.5M ($0.18) in Q2 2022, which included one-time gains.","Cash, equivalents and investments $153.6M as of June 30, 2023; expected runway into Q2 2024 (net cash used in ops $52.8M in Q2).","IND cleared for allogeneic CAR T ATA3219 in relapsed/refractory B-cell NHL; Phase 1 to start in coming months.","FDA meeting scheduled to resolve comparability for tab-cel (EBVALLO) BLA submission; commercial discussions advancing.","Primary analysis of ATA188 Phase 2 EMBOLD study in progressive MS to be communicated in early November with data from >90 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039797","json":"https://secwatch.observer/filing/0000950170-23-039797.json","markdown":"https://secwatch.observer/filing/0000950170-23-039797.md","text":"https://secwatch.observer/filing/0000950170-23-039797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/0000950170-23-039797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/atra-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:04:00.783164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"058f056254d6961bd04d99bdc195d1f755b538b3","claim":"Atara Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $71.1 million, or $0.68 per share for the second quarter 2023.","evidence_excerpt":"Atara reported a net loss of $71.1 million, or $0.68 per share for the second quarter 2023, as compared to net income of $18.5 million, or $0.18 per share for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/0000950170-23-039797-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $71.1 million, or $0.68 per share for the second quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}